FDA to review sintilimab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of people with nonsquamous non-small cell lung cancer

The evidence for the new drug application for this PD-1 inhibitor is from the ORIENT-11 phase 3 trial. Sintilimab is currently being evaluated in a wide variety of cancer types under a broad clinical development program

Source:

Biospace Inc.